Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H+)-ATPase Inhibitors

(2017) Renukadevi Patil et al.   MOLECULES

NHE1 has a notable role in metastasis and drug resistance of T-cell acute lymphoblastic leukemia

(2017) Ehtisham Altaf et al.   Oncology Letters

The global decrease in cancer mortality: trends and disparities

(2016) D. Hashim et al.   ANNALS OF ONCOLOGY

A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer

(2016) Georg Dimcevski et al.   JOURNAL OF CONTROLLED RELEASE

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4

(2016) Candice Sun Hong et al.   Cell Reports

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

(2015) Elizabeth Fox et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors

(2015) Man Yu et al.   CANCER SCIENCE

Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect

(2015) Luana Lugini et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma

(2015) Yoo-Young Lee et al.   Oncotarget

Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer

(2014) Kirsten Lindner et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors

(2013) K. J. Patel et al.   CLINICAL CANCER RESEARCH

Investigating Mechanisms of Alkalinization for Reducing Primary Breast Tumor Invasion

(2013) Ian F. Robey et al.   Biomed Research International

Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cellsin vitro

(2012) Roben G. Gieling et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Doxorubicin Delivery into Tumor Cells with Ultrasound and Microbubbles

(2011) J. M. Escoffre et al.   MOLECULAR PHARMACEUTICS

Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line

(2010) Huan Meng et al.   ACS Nano

Pulsed Ultrasound Enhances Nanoparticle Penetration into Breast Cancer Spheroids

(2010) Stephanie J. Grainger et al.   MOLECULAR PHARMACEUTICS

Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH

(2008) J. Chiche et al.   CANCER RESEARCH

Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene

(2007) Eva María Otero-Rey et al.   ORAL ONCOLOGY